GRAIL, Inc. GRAL Business Segments — Clinical Studies
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by GRAIL, Inc. in its filing.
Tagged under the XBRL concept gral:ClinicalStudiesExpense.
The official record: GRAIL, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about GRAIL, Inc.'s business segments — clinical studies.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is GRAIL, Inc.'s business segments — clinical studies?
- GRAIL, Inc. (GRAL) reported business segments — clinical studies of $5.94M in Q1 2026.
- How has GRAIL, Inc.'s business segments — clinical studies changed year-over-year?
- GRAIL, Inc.'s business segments — clinical studies increased by 0.4% year-over-year, from $5.92M to $5.94M.
- What is the long-term trend for GRAIL, Inc.'s business segments — clinical studies?
- Over 3 years (2022 to 2025), GRAIL, Inc.'s business segments — clinical studies has grown at a -23.9% compound annual growth rate (CAGR), from $63.67M to $28.01M.
- What does business segments — clinical studies mean?
- Includes all direct costs related to conducting clinical trials, research, and development activities necessary for product validation and regulatory approval. For healthcare companies, this represents the primary investment in future product viability and market expansion.